The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy - PubMed (original) (raw)
The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy
S F Kozak et al. Diagn Microbiol Infect Dis. 1998 Feb.
Abstract
The principal side effect of the antimycobacterial agent ethambutol (EMB) is an optic neuropathy with clinical features very similar to a mitochondrial hereditary optic neuropathy (Leber's). The mechanism of EMB-induced optic neuropathy may be EMB's chelation of copper, thereby precluding normal cytochrome c oxidase activity and mitochondrial metabolism in the optic nerve. Before attempting to use therapeutic copper to replenish endogenous stores in an attempt to preclude EMB-induced optic neuropathy, we wished to determine whether EMB is still effective against mycobacteria in the presence of copper. EMB and copper, alone and in combination, were tested against six strains of Mycobacterium tuberculosis and five strains of Mycobacterium avium using a radiometric broth macrodilution assay. Copper did not effect EMB's antimicrobial actions against either species of mycobacteria. This in vitro study suggests that if copper were given to patients to prevent EMB-induced optic neuropathy, it would not compromise EMB's bacteriostatic properties.
Similar articles
- Visual Recovery Time in Patients with Ethambutol-induced Toxic Optic Neuropathy.
An HR, Lee BJ, Moon Y. An HR, et al. Korean J Ophthalmol. 2024 Apr;38(2):91-97. doi: 10.3341/kjo.2023.0095. Epub 2024 Feb 14. Korean J Ophthalmol. 2024. PMID: 38351490 Free PMC article. Review. - In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
Kaur D, Khuller GK. Kaur D, et al. Int J Antimicrob Agents. 2001 Jan;17(1):51-5. doi: 10.1016/s0924-8579(00)00308-3. Int J Antimicrob Agents. 2001. PMID: 11137649 - Incidence of toxic optic neuropathy with low-dose ethambutol.
Yang HK, Park MJ, Lee JH, Lee CT, Park JS, Hwang JM. Yang HK, et al. Int J Tuberc Lung Dis. 2016 Feb;20(2):261-4. doi: 10.5588/ijtld.15.0275. Int J Tuberc Lung Dis. 2016. PMID: 26792482 - Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.
Zoumalan CI, Agarwal M, Sadun AA. Zoumalan CI, et al. Graefes Arch Clin Exp Ophthalmol. 2005 May;243(5):410-6. doi: 10.1007/s00417-004-1053-1. Epub 2004 Nov 23. Graefes Arch Clin Exp Ophthalmol. 2005. PMID: 15565293 - Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis.
Wang T, Jiao WW, Shen AD. Wang T, et al. Yi Chuan. 2016 Oct 20;38(10):910-917. doi: 10.16288/j.yczz.16-111. Yi Chuan. 2016. PMID: 27806932 Review.
Cited by
- Maculopapillary Bundle Degeneration in Optic Neuropathies.
Lambiri DW, Levin LA. Lambiri DW, et al. Curr Neurol Neurosci Rep. 2024 Jul;24(7):203-218. doi: 10.1007/s11910-024-01343-0. Epub 2024 Jun 4. Curr Neurol Neurosci Rep. 2024. PMID: 38833037 Review. - Visual Recovery Time in Patients with Ethambutol-induced Toxic Optic Neuropathy.
An HR, Lee BJ, Moon Y. An HR, et al. Korean J Ophthalmol. 2024 Apr;38(2):91-97. doi: 10.3341/kjo.2023.0095. Epub 2024 Feb 14. Korean J Ophthalmol. 2024. PMID: 38351490 Free PMC article. Review. - Visual outcomes of toxic optic neuropathy secondary to Ethambutol: A retrospective observational study from India, an endemic country.
Ambika S, Lakshmi KP, Gopal M, Noronha OV. Ambika S, et al. Indian J Ophthalmol. 2022 Sep;70(9):3388-3392. doi: 10.4103/ijo.IJO_2996_21. Indian J Ophthalmol. 2022. PMID: 36018127 Free PMC article. - Optic neuropathy induced by ethambutol: A rare case from Nepal.
Shah S, Adhikari YR, Paudel S, Sitaula S, Koirala B, Aryal S, Pande Y, Karki R. Shah S, et al. Ann Med Surg (Lond). 2022 Apr 16;77:103637. doi: 10.1016/j.amsu.2022.103637. eCollection 2022 May. Ann Med Surg (Lond). 2022. PMID: 35638034 Free PMC article. - Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling.
Balhara A, Ladumor MK, Nankar RP, Syed SD, Giri S, Prasad B, Singh S. Balhara A, et al. Pharm Res. 2022 Apr;39(4):677-689. doi: 10.1007/s11095-022-03227-9. Epub 2022 Mar 17. Pharm Res. 2022. PMID: 35301670